Schizophrenia, primary negative symptoms, and soft outcomes in psychiatry

Affiliations

¹ Department of Psychiatry and Psychotherapy, Technische Universität München, Klinikum rechts der Isar, Munich 81675, Germany. Electronic address: stefan.leucht@tum.de.
² Psychiatric Institute, University of Illinois at Chicago, Chicago, IL, USA; Maryland Psychiatric Research Center, Baltimore, MD, USA.

Comment

Stefan Leucht et al. Lancet. 2017.

. 2017 Mar 18;389(10074):1077-1078.

doi: 10.1016/S0140-6736(17)30181-2. Epub 2017 Feb 7.

¹ Department of Psychiatry and Psychotherapy, Technische Universität München, Klinikum rechts der Isar, Munich 81675, Germany. Electronic address: stefan.leucht@tum.de.
² Psychiatric Institute, University of Illinois at Chicago, Chicago, IL, USA; Maryland Psychiatric Research Center, Baltimore, MD, USA.

No abstract available

Comment on

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial.
Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW. Németh G, et al. Lancet. 2017 Mar 18;389(10074):1103-1113. doi: 10.1016/S0140-6736(17)30060-0. Epub 2017 Feb 7. Lancet. 2017. PMID: 28185672 Clinical Trial.